Edwards Lifesciences Corp Irvine, Ca campus-by Steve Cukrov via Shutterstock Neharika Jain Tue, January 13, 2026 at 10:01 PM GMT+8 2 min read In this article: - EW -0.88%
Valued at a market cap of $48.2 billion, Edwards Lifesciences Corporation (EW) is a medical technology company based in Irvine, California. It develops, manufactures, and markets advanced devices used to treat patients with serious heart conditions. The company is scheduled to announce its fiscal Q4 earnings for 2025 in the near future.
Ahead of this event, analysts expect this healthcare company to report a profit of $0.61 per share, up 3.4% from $0.59 per share in the year-ago quarter. The company has topped Wall Street’s bottom-line estimates in each of the last four quarters. In Q3, its EPS of $0.67 exceeded the consensus estimates by 13.6%.
More News from Barchart
-
As Trump Says He Is ‘Proud’ of Intel, Should You Buy INTC Stock?
-
As SanDisk Eyes Doubling Memory Prices, Should You Buy Red-Hot SNDK Stock?
-
As Netflix Drops 33%, Is NFLX Stock Buy Ahead of Q4 Earnings?
-
Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines.
For the current fiscal year, ending in December, analysts expect EW to report a profit of $2.59 per share, up 6.6% from $2.43 per share in fiscal 2024. Its EPS is expected to further grow 12% year-over-year to $2.90 in fiscal 2026.
www.barchart.com EW has gained 13.1% over the past 52 weeks, underperforming the S&P 500 Index's ($SPX) 19.7% return over the same time frame. However, it has outpaced the State Street Health Care Select Sector SPDR ETF’s (XLV) 12.7% uptick over the same time period.
www.barchart.com EW reported its Q3 results on Oct. 30, and its shares plunged 1.2% in the following trading session. Due to strength across all product groups, the company’s net sales increased 14.7% year-over-year to $1.6 billion. Meanwhile, its adjusted EPS remained stable at $0.67 compared with the year-ago quarter but exceeded consensus expectations by a solid 13.6%.
Wall Street analysts are moderately optimistic about EW’s stock, with an overall "Moderate Buy" rating. Among 31 analysts covering the stock, 18 recommend "Strong Buy," two indicate “Moderate Buy," and 11 suggest "Hold.” The mean price target for EW is $96.32, indicating a 16% potential upside from the current levels.
On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Terms and Privacy Policy Privacy Dashboard More Info
